AbbVie's first shot at Vertex misses, but it's not abandoning cystic fibrosis
Bio Pharma Dive
APRIL 29, 2022
Executives on Friday said that the company's three-drug therapy, a possible threat to Vertex's top-selling medicine Trikafta, didn't meet expectations in a key study. A new combination could start testing next year, however.
Let's personalize your content